Posted On: 01/10/2013 7:43:29 PM
Post# of 72447
I wouldnt rule out- Tremendous news for CTIX - nor would I be convinced
It was right there in the CTIX PR about the cohort continuing to receive dosing after their cycle was finished.
Quote:
At this time, first cohort patients are about to begin their third cycle of dosing and the second cohort – in which dosing levels were doubled – are in their first cycle of dosing. The information that we have received at this early stage of the trial so far has been very encouraging with no data being delivered outside of the parameters of the protocol.
We just didn't understand that this required a measurable benefit confirmed by scans. Otherwise the first cohort of patients would have been finished with the trial after their first dosing cycle.
Quote:
A participant can advance to the next cycle assuming they tolerate the drug and perceive a benefit (stable disease or improvement) if scans are performed.
Stable disease or improvement is NOT typical for late stage cancer patients with tumours not helped by existing available treatments.
It also tells us that kevetrin is tolerable at that dose for three consecutive cycles, and that there is benefit at even the small starting dose of the trial.
Fantastic clarification. When the market wakes up to this things should look even better for the share price, but I'm just happy to hear that the patients in the study are getting benefit.
It was right there in the CTIX PR about the cohort continuing to receive dosing after their cycle was finished.
Quote:
At this time, first cohort patients are about to begin their third cycle of dosing and the second cohort – in which dosing levels were doubled – are in their first cycle of dosing. The information that we have received at this early stage of the trial so far has been very encouraging with no data being delivered outside of the parameters of the protocol.
We just didn't understand that this required a measurable benefit confirmed by scans. Otherwise the first cohort of patients would have been finished with the trial after their first dosing cycle.
Quote:
A participant can advance to the next cycle assuming they tolerate the drug and perceive a benefit (stable disease or improvement) if scans are performed.
Stable disease or improvement is NOT typical for late stage cancer patients with tumours not helped by existing available treatments.
It also tells us that kevetrin is tolerable at that dose for three consecutive cycles, and that there is benefit at even the small starting dose of the trial.
Fantastic clarification. When the market wakes up to this things should look even better for the share price, but I'm just happy to hear that the patients in the study are getting benefit.
(0)
(0)
